Appropriate use of antimicrobial therapy for COVID-19 co-infection

Immunotherapy. 2021 Sep;13(13):1067-1070. doi: 10.2217/imt-2021-0134. Epub 2021 Jun 11.

Authors

Chih-Cheng Lai¹, Wen-Liang Yu^{2

3}

Affiliations

¹ Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan.
² Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
³ Department of Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

No abstract available

Keywords: Aspergillus; COVID-19; antimicrobial agents; bacteria; co-infection; mucormycosis; respiratory virus.

Publication types

Editorial
Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
Anti-Infective Agents* / therapeutic use
COVID-19*
Coinfection* / drug therapy
Humans
SARS-CoV-2

Substances

Anti-Bacterial Agents
Anti-Infective Agents